title: [Ipilimumab treatment of metastatic melanoma].
abstract: Until recently metastatic melanoma was a disease with limited treatment options and a poor prognosis. However, new promising products have been developed. Ipilimumab, a full human anti-cytotoxic T-lymphocyte antigen-4 antibody, has shown improved survival in several clinical trials and is now a part of the standard treatment options for this disease in Denmark. In this case report we present a 78-year-old man with metastatic melanoma who had complete remission after treatment with ipilimumab.
authors.affiliation: Ortopædkirurgisk Afdeling E, Aarhus Universitetshospital, Nørrebrogade 44, 8000 Aarhus C. habib@dadlnet.dk.
authors.forename: Habib
authors.initials: H
authors.lastname: Ghasemi
authors.forename: Henrik
authors.initials: H
authors.lastname: Schmidt
authors.forename: Lars Bjørn
authors.initials: LB
authors.lastname: Stolle
mesh_terms: D000368:Aged; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006801:Humans; D000074324:Ipilimumab; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D009362:Neoplasm Metastasis / Q000188:drug therapy / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D016896:Treatment Outcome
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000074324:Ipilimumab